RNAs are essential for the functioning of a healthy nervous system, but the dysfunction of coding and noncoding RNAs causes many devastating neurodegenerative disorders. In Huntington's disease, CAG-repeat expansions encode polyglutamine tracts in one allele of the huntingtin gene. Both the CAG repeat-containing mRNAs and the translated polyQ protein cause pathology. The huntingtin transcript containing expanded CAG repeats adopts a structure distinct from that formed by the normal mRNA, and the unique disease-associated RNA tertiary structure is a prime target for the development of novel therapeutics. RNA is a compelling target for small-molecule drug discovery, and a three-dimensional RNA structure found only in the disease-associated huntingtin mRNA offers an opportunity for the development of allele-specific small molecules. Multiple natural products target ribosomal RNA, establishing proof of concept for RNA as a drug target; however, RNA-targeted drug discovery remains a nascent field. We are ideally positioned to develop, validate, and apply a screening system to identify small-molecule ligands that specifically target the unique tertiary structure adopted by the disease-related huntingtin mRNA. Our proposed screening platform combines an initial very rapid and high-throughput microarray screen with a secondary assay based on SHAPE technology, the gold standard for RNA structure analyses. This platform will include controls that enforce high specificity of ligand for the target RNA. Following successful validation of this platform in the R21 phase, we will apply the platform to identify small molecules that specifically bind to the disease-associated huntingtin allele in the R33 phase. Validation and initial medicinal chemistry development of hit compounds will serve as a foundation for the development of novel therapies for Huntington's disease with the opportunity to access an unprecedented level of selectivity. The majority of RNAs share broadly similar overall properties, so a strategy that allows RNA to be targeted in a single case will likely allow targeting of diverse therapeutically important RNAs. The long-term vision of Ribometrix is to apply this platform technology to discover small-molecule therapeutics that target functional RNA structures involved in indications for which there are no approved therapies, including Huntington's disease. We are poised to fully validate and apply an efficient and generic approach for RNA-targeted ligand discovery by targeting an RNA structure unique to the pathogenic disease-causing huntingtin allele.

Public Health Relevance

RNA plays a critical role in the pathology of many devastating neurodegenerative diseases including Huntington's disease. This project will validate and apply innovative technology to identify compounds that bind to an RNA tertiary structure unique to the CAG-repeat expanded htt mRNA present in afflicted individuals but not in the normal htt mRNA; these small molecules will serve as the foundation for the development of novel, highly selective small-molecule therapies. RNA is an under-explored drug target, and this project aims both to identify lead compounds for Huntington's disease and to define principles of RNA-targeted drug discovery that will broadly facilitate the development of therapeutics targeting pathogenic RNAs across diverse disease states.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Roof, Rebecca
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ribometrix, LLC
United States
Zip Code